309 related articles for article (PubMed ID: 22748660)
41. Infusion of CARv3-TEAM-E T Cells in Glioblastoma.
Wong ET
N Engl J Med; 2024 Jun; 390(24):2330. PubMed ID: 38924745
[No Abstract] [Full Text] [Related]
42. IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors.
Joalland N; Chauvin C; Oliver L; Vallette FM; Pecqueur C; Jarry U; Scotet E
J Immunother; 2018 Jun; 41(5):224-231. PubMed ID: 29683891
[TBL] [Abstract][Full Text] [Related]
43. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
[TBL] [Abstract][Full Text] [Related]
44. Challenges in clinical design of immunotherapy trials for malignant glioma.
Rolle CE; Sengupta S; Lesniak MS
Neurosurg Clin N Am; 2010 Jan; 21(1):201-14. PubMed ID: 19944979
[TBL] [Abstract][Full Text] [Related]
45. Immunotherapy of intracranial G422 glioblastoma with dendritic cells pulsed with tumor extract or RNA.
Zhang Z; Tang LL; Zhan RY; Tong Y; Yao HP; Du LA
J Zhejiang Univ Sci; 2004 Oct; 5(10):1298-303. PubMed ID: 15362204
[TBL] [Abstract][Full Text] [Related]
46. Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme.
Lazovic J; Jensen MC; Ferkassian E; Aguilar B; Raubitschek A; Jacobs RE
Clin Cancer Res; 2008 Jun; 14(12):3832-9. PubMed ID: 18559603
[TBL] [Abstract][Full Text] [Related]
47. Induction of human autologous cytotoxic T lymphocytes against minced tissues of glioblastoma multiforme.
Tsurushima H; Liu SQ; Tsuboi K; Yoshii Y; Nose T; Ohno T
J Neurosurg; 1996 Feb; 84(2):258-63. PubMed ID: 8592229
[TBL] [Abstract][Full Text] [Related]
48. Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development.
Majc B; Novak M; Kopitar-Jerala N; Jewett A; Breznik B
Cells; 2021 Jan; 10(2):. PubMed ID: 33572835
[TBL] [Abstract][Full Text] [Related]
49. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
Everson RG; Graner MW; Gromeier M; Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS; Friedman AH; Bigner DD; Sampson JH
Expert Rev Anticancer Ther; 2008 May; 8(5):717-32. PubMed ID: 18471045
[TBL] [Abstract][Full Text] [Related]
50. Cell-Based Immunotherapy of Gliomas.
Everson RG; Antonios JP; Liau LM
Prog Neurol Surg; 2018; 32():90-100. PubMed ID: 29990977
[TBL] [Abstract][Full Text] [Related]
51. Benefits of a continuous therapy for cancer patients with a novel adoptive cell therapy by cascade priming (CAPRI).
Wank R; Song X; Gu S; Laumbacher B
Immunotherapy; 2014; 6(3):269-82. PubMed ID: 24762072
[TBL] [Abstract][Full Text] [Related]
52. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM
Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936
[TBL] [Abstract][Full Text] [Related]
53. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
Yoshida S; Takai N; Ono K; Saito T; Tanaka R
No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
[TBL] [Abstract][Full Text] [Related]
54. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens.
Xu Q; Liu G; Yuan X; Xu M; Wang H; Ji J; Konda B; Black KL; Yu JS
Stem Cells; 2009 Aug; 27(8):1734-40. PubMed ID: 19536809
[TBL] [Abstract][Full Text] [Related]
55. [Cellular immunotherapy for malignant glioma].
Okamoto Y; Yamashita J
Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
[No Abstract] [Full Text] [Related]
56. The role of checkpoints in the treatment of GBM.
Kim JE; Lim M
J Neurooncol; 2015 Jul; 123(3):413-23. PubMed ID: 25749875
[TBL] [Abstract][Full Text] [Related]
57. [Not Available].
Baldini C; Romano PM; Varga A; Champiat S; Dumont S; Dhermain F; Louvel G; Marabelle A; Postel-Vinay S; Angevin E; Gazzah A; Ribrag V; Bahleda R; Michot JM; Hollebecque A; Soria JC; Massard C
Bull Cancer; 2018 Dec; 105 Suppl 1():S59-S67. PubMed ID: 30595200
[TBL] [Abstract][Full Text] [Related]
58. Glioblastoma Therapy in the Age of Molecular Medicine.
Geraldo LHM; Garcia C; da Fonseca ACC; Dubois LGF; de Sampaio E Spohr TCL; Matias D; de Camargo Magalhães ES; do Amaral RF; da Rosa BG; Grimaldi I; Leser FS; Janeiro JM; Macharia L; Wanjiru C; Pereira CM; Moura-Neto V; Freitas C; Lima FRS
Trends Cancer; 2019 Jan; 5(1):46-65. PubMed ID: 30616755
[TBL] [Abstract][Full Text] [Related]
59. Strategies using the immune system for therapy of brain tumors.
Virasch N; Kruse CA
Hematol Oncol Clin North Am; 2001 Dec; 15(6):1053-71. PubMed ID: 11770298
[TBL] [Abstract][Full Text] [Related]
60. Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial.
Lim J; Park Y; Ahn JW; Sim J; Kang SJ; Hwang S; Chun J; Choi H; Kim SH; Chun DH; Sung KS; Kwack K; Cho K
PLoS One; 2021; 16(3):e0247293. PubMed ID: 33690665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]